amantadine
E229732
NMDA receptor antagonist
adamantane derivative
antiparkinsonian agent
antiviral drug
dopaminergic agent
Amantadine is an antiviral and antiparkinsonian medication used to help manage motor symptoms such as tremor and rigidity in people with Parkinson’s disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| amantadine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2033084 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: amantadine Context triple: [Parkinson's disease, hasTreatment, amantadine]
-
A.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
B.
oseltamivir
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
-
C.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
D.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
E.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: amantadine Target entity description: Amantadine is an antiviral and antiparkinsonian medication used to help manage motor symptoms such as tremor and rigidity in people with Parkinson’s disease.
-
A.
zanamivir
Zanamivir is an inhaled neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B infections, including strains such as the 2009 H1N1 virus.
-
B.
oseltamivir
Oseltamivir is an oral antiviral medication (commonly known by the brand name Tamiflu) used to treat and prevent influenza, including pandemic strains such as 2009 H1N1.
-
C.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
D.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
E.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
NMDA receptor antagonist
ⓘ
adamantane derivative ⓘ antiparkinsonian agent ⓘ antiviral drug ⓘ dopaminergic agent ⓘ |
| availableAs |
oral capsule
ⓘ
oral syrup ⓘ oral tablet ⓘ |
| contraindicatedIn |
severe renal impairment
ⓘ
untreated angle-closure glaucoma ⓘ |
| developedInDecade | 1960s ⓘ |
| eliminationRoute | renal excretion ⓘ |
| hasATCCode |
J05BB01
ⓘ
N04BB01 ⓘ |
| hasBrandName | Symmetrel ⓘ |
| hasCASNumber | 768-94-5 ⓘ |
| hasChemicalFormula | C10H17N ⓘ |
| hasIUPACName | 1-adamantanamine ⓘ |
| hasMolarMass | 151.25 g/mol ⓘ |
| isObsoleteFor |
routine influenza A prophylaxis
ⓘ
routine influenza A treatment ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mayCauseAdverseEffect |
confusion
ⓘ
constipation ⓘ dry mouth ⓘ hallucinations ⓘ insomnia ⓘ livedo reticularis ⓘ orthostatic hypotension ⓘ peripheral edema ⓘ urinary retention ⓘ |
| mechanismOfAction |
increased dopamine release
ⓘ
inhibition of dopamine reuptake ⓘ interference with influenza A viral uncoating ⓘ noncompetitive NMDA receptor antagonism ⓘ weak anticholinergic effect ⓘ |
| pregnancyCategoryUS | C ⓘ |
| requiresDoseAdjustmentIn | renal impairment ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
NMDA receptor
ⓘ
dopaminergic neurons ⓘ |
| usedFor |
Parkinson's disease
ⓘ
Parkinsonian bradykinesia ⓘ Parkinsonian dyskinesia ⓘ Parkinsonian rigidity ⓘ Parkinsonian tremor ⓘ drug-induced extrapyramidal symptoms ⓘ influenza A infection ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: amantadine Description of subject: Amantadine is an antiviral and antiparkinsonian medication used to help manage motor symptoms such as tremor and rigidity in people with Parkinson’s disease.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.